TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Entheon Biomedical ( (TSE:ENBI) ) is now available.
Entheon Biomedical Corp. has entered into an agreement to acquire Mentis AI, a company specializing in AI technologies for mental health and loneliness. The acquisition will allow Entheon to integrate AI tools into its platforms, enhancing customer relationships and expanding its service offerings. Mentis AI shareholders will receive Entheon shares, owning approximately 44.25% post-transaction, subject to due diligence and regulatory approvals.
More about Entheon Biomedical
Entheon Biomedical Corp. operates in the biomedical industry, focusing on psychedelic and cannabis genetic testing kits. The company aims to enhance mental health and wellness by understanding user experiences and outcomes through its test kits.
YTD Price Performance: -16.79%
Average Trading Volume: 3,455
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $1.91M
For a thorough assessment of ENBI stock, go to TipRanks’ Stock Analysis page.